Qian Zhang

Dr. Zhang joined Genelux Corporation as one of the founding scientists in January 2003. She served as Director of Molecular Biology for five years, responsible for design and engineering of protein expression constructs, tumor targeting, immune modulation, imaging, radiation sensitizing, and oncolytic viral therapy. She extensively investigated the genomic, proteomic and host expression profiles of various vaccinia strains, including Olvi-Vec(GL-ONC1), the leading product in the pipeline. She has had increasing responsibilities since 2008 as Associate Vice President of Medical Regulatory Affairs, serving as the regulatory contact in preparing and submitting regulatory documents, ensuring GMP product testing in accordance with FDA and EMA requirements, reviewing clinical protocols for regulatory compliance and quality assurance, and developing and evaluating laboratory SOPs for testing of clinical samples.

Dr. Zhang has authored more than 40 scientific publications in peer reviewed journals and holds numerous U.S. Patents. She earned her Ph.D. in Physiology and Molecular Biology and Master’s in Public Health (MPH) from Loma Linda University, and her Bachelor’s in Medicine from Qingdao University Medical College (aka Qingdao Medical College), China (ACEI certified to be equivalent to the first professional degree of Doctor of Medicine). She practiced for five years in Internal Medicine with emphasis on Cardiology and Geriatrics.